Optibiotix Health has successfully raised US$1.3 million though a placing of new shares
Optibiotix Health Plc has completed a fundraising to continue the commercialization of its products with corporate and large retail partners, with a particular focus on the company’s SweetBiotix©.
OptiBiotix Health is a life sciences company operating in one of the most progressive areas of biotechnological research. Developing technologies that modulate the human microbiome – the collective genome of the microbes in the body – OptiBiotix identifies and develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. With an established pipeline of microbiome modulators, the OptiBiotix team is working in the prevention and management of chronic lifestyle diseases including obesity, hypercholesterolemia and lipid profiles and diabetes.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Optibiotix Health on its equity fundraising.
Contáctese con el equipo de la transacción
Transacciones relacionadas
Xeros Technology Group has completed a placing, subscription and retail offer
Xeros Technology Group plc has raised funds to drive forward its commercialization strategy.
Aprenda másPCI Pal has completed an equity raise
PCI Pal has completed a fundraising. Funds will be allocated towards several key areas, with a significant portion directed towards supporting its continued expansion in the US, focusing on marketing efforts, product marketing and enhancing engagement with key partners.
Aprenda másCARSO Group has acquired a majority stake in AQCF Group
CARSO Group, a leading provider of testing services, has acquired a majority stake in AQCF Group, a key player in the field of food safety.
Aprenda más